Trial Profile
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.